Status:
COMPLETED
Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532
Lead Sponsor:
Pfizer
Conditions:
Healthy
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the excretion balance, metabolic profile and the routes of excretion of \[14C\]PF-04991532 in healthy adult male subjects.
Eligibility Criteria
Inclusion
- Healthy male subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg(110 lbs).
- An informed consent document signed and dated by the subject.
Exclusion
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or clinical findings at Screening.
- History of irregular bowel movements (eg, irritable bowel syndrome or frequent episodes of diarrhea or constipation).
- Any condition possibly affecting drug absorption (eg, appendectomy, gastrectomy).
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2011
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01469481
Start Date
November 1 2011
End Date
November 1 2011
Last Update
January 31 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Tacoma, Washington, United States, 98418